FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521717745> ?p ?o ?g. }

• W2521717745 endingPage "3272" @default.
• W2521717745 startingPage "3264" @default.
• W2521717745 abstract "Despite great histological and molecular heterogeneity, the clinical management of high-grade ovarian carcinomas remains unspecialized. As a major subgroup, high-grade serous ovarian carcinomas (HGSOCs) require novel therapies. In addition to utilizing conventional histological prognostic markers and performing oncogenetic investigations, the molecular diagnostic method of next generation sequencing (NGS) was performed to identify 'druggable' targets that could provide access to innovative therapy. The present study was performed in 45 HGSOC patients (mean age, 59.1 years; range, 25-87 years) with histologically proven HGSOC. Breast cancer 1/2 (BRCA1/2) germline mutations were screened in 17 patients with a familial or personal history of cancer, which was justified by oncogenetic investigations. Tumor protein 53 (P53) and phosphatase and tensin homolog (PTEN) expression were assessed in formalin-fixed paraffin-embedded tissues using immunohistochemistry. Somatic mutations of Kirsten rat sarcoma viral oncogene homolog, neuroblastoma RAS viral oncogene homolog (NRAS), B-Raf proto-oncogene, serine/threonine kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) and MET proto-oncogene, receptor tyrosine kinase (MET) were screened using NGS on DNA extracts from frozen tumor specimens obtained at diagnosis. With a median follow-up of 38 months (range, 6-93 months), 20 patients are alive, 10 patients are disease-free and 14 patients progressed within 6 months following platinum-based therapy. P53 overexpression was detected in 67% of patients and PTEN loss was detected in 38% of the patients. The overexpression of mutant P53 was found to be associated with a longer progression-free and overall survival. In total, 2 NRAS (exon 3), 3 PIK3CA (exon 5 and 10) and 5 MET mutations (exons 14 and 18) were detected. In HGSOCs, in addition to P53 and PTEN alterations, somatic genetic abnormalities can be detected using NGS and provide molecular rationale for targeted therapies, potentially offering novel therapeutic opportunities to patients." @default.
• W2521717745 created "2016-09-30" @default.
• W2521717745 creator A5002706540 @default.
• W2521717745 creator A5003880256 @default.
• W2521717745 creator A5021594493 @default.
• W2521717745 creator A5023641799 @default.
• W2521717745 creator A5052695728 @default.
• W2521717745 creator A5053674695 @default.
• W2521717745 creator A5072355411 @default.
• W2521717745 creator A5075141136 @default.
• W2521717745 date "2016-09-02" @default.
• W2521717745 modified "2023-10-08" @default.
• W2521717745 title "Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets" @default.
• W2521717745 cites W1793338775 @default.
• W2521717745 cites W1965596636 @default.
• W2521717745 cites W1967187359 @default.
• W2521717745 cites W1994563300 @default.
• W2521717745 cites W2003273433 @default.
• W2521717745 cites W2014135632 @default.
• W2521717745 cites W2014627554 @default.
• W2521717745 cites W2024297717 @default.
• W2521717745 cites W2040330598 @default.
• W2521717745 cites W2075676198 @default.
• W2521717745 cites W2090968329 @default.
• W2521717745 cites W2092639306 @default.
• W2521717745 cites W2094337993 @default.
• W2521717745 cites W2100898204 @default.
• W2521717745 cites W2101982508 @default.
• W2521717745 cites W2102306754 @default.
• W2521717745 cites W2106893529 @default.
• W2521717745 cites W2114556798 @default.
• W2521717745 cites W2116005493 @default.
• W2521717745 cites W2116095691 @default.
• W2521717745 cites W2117430947 @default.
• W2521717745 cites W2117514753 @default.
• W2521717745 cites W2118087314 @default.
• W2521717745 cites W2123696077 @default.
• W2521717745 cites W2137218317 @default.
• W2521717745 cites W2138896702 @default.
• W2521717745 cites W2139712038 @default.
• W2521717745 cites W2142233318 @default.
• W2521717745 cites W2142315771 @default.
• W2521717745 cites W2144187284 @default.
• W2521717745 cites W2154841567 @default.
• W2521717745 cites W2155103465 @default.
• W2521717745 cites W2155341026 @default.
• W2521717745 cites W2158040154 @default.
• W2521717745 cites W2161701941 @default.
• W2521717745 cites W2170552969 @default.
• W2521717745 cites W2190017347 @default.
• W2521717745 cites W2269804053 @default.
• W2521717745 cites W2281254500 @default.
• W2521717745 cites W2411434284 @default.
• W2521717745 cites W2908428008 @default.
• W2521717745 cites W2917837889 @default.
• W2521717745 cites W4211147776 @default.
• W2521717745 cites W4298797619 @default.
• W2521717745 cites W824117529 @default.
• W2521717745 doi "https://doi.org/10.3892/ol.2016.5083" @default.
• W2521717745 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5103928" @default.
• W2521717745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27899992" @default.
• W2521717745 hasPublicationYear "2016" @default.
• W2521717745 type Work @default.
• W2521717745 sameAs 2521717745 @default.
• W2521717745 citedByCount "15" @default.
• W2521717745 countsByYear W25217177452017 @default.
• W2521717745 countsByYear W25217177452018 @default.
• W2521717745 countsByYear W25217177452019 @default.
• W2521717745 countsByYear W25217177452020 @default.
• W2521717745 countsByYear W25217177452021 @default.
• W2521717745 countsByYear W25217177452023 @default.
• W2521717745 crossrefType "journal-article" @default.
• W2521717745 hasAuthorship W2521717745A5002706540 @default.
• W2521717745 hasAuthorship W2521717745A5003880256 @default.
• W2521717745 hasAuthorship W2521717745A5021594493 @default.
• W2521717745 hasAuthorship W2521717745A5023641799 @default.
• W2521717745 hasAuthorship W2521717745A5052695728 @default.
• W2521717745 hasAuthorship W2521717745A5053674695 @default.
• W2521717745 hasAuthorship W2521717745A5072355411 @default.
• W2521717745 hasAuthorship W2521717745A5075141136 @default.
• W2521717745 hasBestOaLocation W25217177451 @default.
• W2521717745 hasConcept C121608353 @default.
• W2521717745 hasConcept C126322002 @default.
• W2521717745 hasConcept C142724271 @default.
• W2521717745 hasConcept C150173356 @default.
• W2521717745 hasConcept C21790070 @default.
• W2521717745 hasConcept C2777609662 @default.
• W2521717745 hasConcept C2781018059 @default.
• W2521717745 hasConcept C2781187634 @default.
• W2521717745 hasConcept C2781465904 @default.
• W2521717745 hasConcept C29537977 @default.
• W2521717745 hasConcept C502942594 @default.
• W2521717745 hasConcept C526805850 @default.
• W2521717745 hasConcept C55493867 @default.
• W2521717745 hasConcept C62478195 @default.
• W2521717745 hasConcept C67082663 @default.
• W2521717745 hasConcept C71924100 @default.
• W2521717745 hasConcept C75217442 @default.

• next